GT Biopharma, Inc.
General ticker "GTBP" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $4.4M (TTM average)
GT Biopharma, Inc. does not follow the US Stock Market performance with the rate: -34.5%.
Estimated limits based on current volatility of 8.4%: low 0.64$, high 0.75$
Factors to consider:
- Total employees count: 1 as of 2024
- Top business risk factors: Operational and conduct risks, Manufacturing risks, Labor/talent shortage/retention, Market competition, Reimbursement risks
- Current price 53.8% below estimated low
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [1.36$, 5.40$]
- 2025-12-31 to 2026-12-31 estimated range: [0.71$, 3.01$]
Financial Metrics affecting the GTBP estimates:
- Positive: with PPE of -0.4 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -255.73 <= 0.33
- Positive: Inventory ratio change, % of 0 <= 0
- Positive: Investing cash flow per share per price, % of 255.51 > -0.66
- Negative: negative Industry operating cash flow (median)
- Negative: Shareholder equity ratio, % of -39.46 <= 18.93
- Negative: negative Net income
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term GTBP quotes
Long-term GTBP plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $21.26MM | $13.58MM | $14.36MM |
| Operating Income | $-21.26MM | $-13.58MM | $-14.36MM |
| Non-Operating Income | $0.37MM | $5.98MM | $1.20MM |
| Interest Expense | $0.01MM | $0.21MM | $0.00MM |
| R&D Expense | $8.81MM | $6.47MM | $5.80MM |
| Income(Loss) | $-20.88MM | $-7.60MM | $-13.16MM |
| Profit(Loss)* | $-20.88MM | $-7.60MM | $-13.16MM |
| Stockholders Equity | $11.73MM | $7.48MM | $-1.67MM |
| Assets | $16.74MM | $14.11MM | $4.23MM |
| Operating Cash Flow | $-15.22MM | $-8.85MM | $-12.90MM |
| Investing Cash Flow | $12.14MM | $-2.01MM | $12.89MM |
| Financing Cash Flow | $-0.22MM | $6.27MM | $2.98MM |
| Earnings Per Share** | $-0.66 | $-5.64 | $-6.94 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.